On March 20, 2025, MetaVia Inc. (MTVA) announced financial results for 2024 and provided a business update. We anticipate topline results from the multiple ascending dose (MAD) Part 2 of the Phase 1 trial of DA-1726 to be reported in April 2025. DA-1726 is the company's novel dual oxyntomodulin analog that functions as a dual glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist. While market conditions and sentiment continue to trend negative for the biotech sector as a whole, the one exception appears to be the obesity space. Just in the past month three deals were announced, indicating that Big Pharma continues to be interested in acquiring differentiated obesity therapies.
